| Dr Amy Mclaren Arrington, DMD | |
|
2060 Charlie Hall Blvd Ste 5a, Charleston, SC 29414-6091 | |
| (614) 499-3361 | |
| Not Available |
| Full Name | Dr Amy Mclaren Arrington |
|---|---|
| Gender | Female |
| Speciality | Dentist - General Practice |
| Location | 2060 Charlie Hall Blvd Ste 5a, Charleston, South Carolina |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1225769318 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 1223G0001X | Dentist - General Practice | 10241 (South Carolina) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dr Amy Mclaren Arrington, DMD 615 Cloudbreak Ct, Charleston, SC 29412-2763 Ph: (614) 499-3361 | Dr Amy Mclaren Arrington, DMD 2060 Charlie Hall Blvd Ste 5a, Charleston, SC 29414-6091 Ph: (614) 499-3361 |
News Archive
UCLA/VA scientists have identified a new gene that controls how the body produces and uses fat. Called lipin, the gene may provide a new target for therapies to control obesity, diabetes and other weight-related disorders. The first issue of the new journal Cell Metabolism publishes the findings in its January 2005 edition.
Homeless patients made about 100,000 visits to California hospitals in 2017, marking a 28% rise from two years earlier, according to the most recent state discharge data.
Brain imaging soon after mild traumatic brain injury or mild concussion can detect tiny lesions that may eventually provide a target for treating people with mTBI, according to a study released today and that will be presented at the American Academy of Neurology's 65th Annual Meeting in San Diego, March 16 to 23, 2013.
Tolerx, Inc., a biopharmaceutical company developing novel therapies to treat autoimmune diseases and cancer by modulating T cell activity, today announced that it has initiated a Phase 1 clinical trial to assess the safety, tolerability, pharmacokinetic, and pharmacodynamic profiles of TRX518, a monoclonal antibody designed to enhance the immune system by enabling T cells to more effectively attack cancer cells.
Scientists at Bonn University Hospital and at the Max Planck Institute for neurological research in Cologne have developed a method with which the chances of success of a surgical procedure for temporal lobe epilepsy can be accurately predicted. The rate of accurate predictions is more than 90%. The results are now being presented in the scientific journal "NeuroImage:Clinical."
› Verified 6 days ago
Dr. Mary Victoria Tatum, DMD Dentist Medicare: Not Enrolled in Medicare Practice Location: 92 Courtenay Dr, Charleston, SC 29403 Phone: 843-577-6112 Fax: 843-937-0200 | |
Adam M Clark, DMD Dentist Medicare: Not Enrolled in Medicare Practice Location: 1416 Ashley River Rd, Atlantic Aesthetics, Charleston, SC 29407 Phone: 843-769-0488 Fax: 843-769-0428 | |
Dr. James Randall Marshall, D.M.D. Dentist Medicare: Not Enrolled in Medicare Practice Location: 29 Bee Street, Dc 500, Charleston, SC 29425 Phone: 843-792-1904 Fax: 843-792-2212 | |
Dr. Fabio Rizzante, DDS, MSC, PHD, MBA Dentist Medicare: Not Enrolled in Medicare Practice Location: 29 Bee Street, Charleston, SC 29425 Phone: 734-489-2834 | |
Dr. James Elliott Gregory Jr., DMD Dentist Medicare: Not Enrolled in Medicare Practice Location: 1812 Wallace School Rd, Charleston, SC 29407 Phone: 843-571-4411 | |
Dr. Theodore D Ravenel V, DMD Dentist Medicare: Medicare Enrolled Practice Location: 173 Ashley Ave, Charleston, SC 29425 Phone: 843-792-3661 | |
Dr. Robert Louis Morrow Sr., DMD Dentist Medicare: Not Enrolled in Medicare Practice Location: 18 A Leinbach Dr., Charleston, SC 29407 Phone: 843-795-3339 |